We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
RSC Holds 5th Conference on High Throughput Medicinal Chemistry
News

RSC Holds 5th Conference on High Throughput Medicinal Chemistry

RSC Holds 5th Conference on High Throughput Medicinal Chemistry
News

RSC Holds 5th Conference on High Throughput Medicinal Chemistry

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "RSC Holds 5th Conference on High Throughput Medicinal Chemistry"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Royal Society of Chemistry’s (RSC) 5th High Throughput Medicinal Chemistry Conference takes place on 12th May 2009 at Alderley Park in Cheshire, UK.

The event will explore technology-enabled drug discovery as well as new synthetic technologies, with a particular focus on medicinal chemistry. As such, this conference will benefit a wide range of organic and medicinal chemists.

Since its conception, the RSC’s High Throughput Chemistry and New Technologies subject group has sought to highlight significant advances in the field, from the pharmaceutical, industrial and academic points of view.

Its 5th conference will focus specifically on: CH activation, Pd coupling, flow chemistry, fragment-based drug discovery and drug discovery in academia. This conference features line-up of speakers, including Greg Fu, MIT; Steven Woodhead, Astex Therapeutics; Rob Maleczka, Michigan State University; Paul Watts, University of Hull; and John G Cumming, Astra Zeneca.
Advertisement